Goerdt, Lukas
Berger, Moritz
Jungblut, Julie
Rodriguez Garcia, Jose Luis
Pfau, Kristina
Herrmann, Philipp
Holz, Frank G.
Wintergerst, Maximilian W. M.
Funding for this research was provided by:
Lowy Medical Research Institute
Universitätsklinikum Bonn
Article History
Received: 3 March 2024
Accepted: 16 July 2024
First Online: 27 July 2024
Competing interests
: Lukas Goerdt: BioEQ/Formycon (C), Novartis Pharma GmbH (R), Bayer AG (R) Moritz Berger: none Julie Jungblut: none Jose Luis Rodriguez Garcia: none Kristina Pfau: Daiichi Sankyo (C) Philipp Herrmann: Novartis (R, F), Janssen (C, R) Frank G. Holz: Acucela (C,F), Alexion (C), Alzheon (C), Allergan (F), Apellis (C, F), Astellas (C), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq/Formycon (F,C), CenterVue (F), Roche/Genentech (C,F), Geuder (C,F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C,F), IvericBio (C, F), Janssen (C), Kanghong (C,F), LinBioscience (C), NightStarX (F), Novartis (C,F), Optos (F), Oxurion (C), Pixium Vision (C,F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (F,C), GRADE Reading Center (O) Maximilian W.M. Wintergerst: ASKIN & CO GmbH (R), Bayer AG (R), Berlin-Chemie AG (R, F), CenterVue SpA (F), Carl Zeiss Meditec (F), D-Eye Srl (F), DigiSight Technologies (R, F), Eyenuk, Inc. (F), Eyepress Fachmedien GmbH (R), glaucare GmbH (O, C), Heine Optotechnik GmbH (C, R, F), Heidelberg Engineering (R, F), Novartis Pharma GmbH (R, F), Optos (F), Pro Generika e.V. (R), Science Consulting in Diabetes GmbH (R).